LeMaitre Vascular Inc (NASDAQ:LMAT) has been assigned an average rating of “Buy” from the eleven brokerages that are presently covering the company, MarketBeat.com reports. Four investment analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $33.25.
Several equities research analysts have recently issued reports on the company. Zacks Investment Research upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $34.00 price target for the company in a report on Wednesday, July 29th. Canaccord Genuity boosted their target price on shares of LeMaitre Vascular from $28.00 to $30.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. BidaskClub raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Friday, September 11th. Stifel Nicolaus raised their target price on LeMaitre Vascular from $25.00 to $30.00 and gave the company a “hold” rating in a report on Friday, July 24th. Finally, Lake Street Capital increased their price objective on LeMaitre Vascular from $33.00 to $38.00 and gave the company a “buy” rating in a report on Friday, July 24th.
In other news, Director David B. Roberts acquired 7,074 shares of the firm’s stock in a transaction dated Friday, August 14th. The shares were bought at an average price of $28.35 per share, with a total value of $200,547.90. Following the acquisition, the director now owns 43,557 shares of the company’s stock, valued at $1,234,840.95. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Trent G. Kamke sold 13,804 shares of the business’s stock in a transaction that occurred on Friday, July 24th. The shares were sold at an average price of $33.00, for a total value of $455,532.00. Following the sale, the insider now owns 21,558 shares in the company, valued at $711,414. The disclosure for this sale can be found here. 16.50% of the stock is owned by corporate insiders.
Several large investors have recently added to or reduced their stakes in the company. Bank of Montreal Can increased its stake in LeMaitre Vascular by 836.2% in the second quarter. Bank of Montreal Can now owns 3,052 shares of the medical instruments supplier’s stock valued at $79,000 after acquiring an additional 2,726 shares during the period. Advisor Group Holdings Inc. bought a new position in shares of LeMaitre Vascular during the 1st quarter worth approximately $155,000. BNP Paribas Arbitrage SA boosted its stake in LeMaitre Vascular by 78.3% in the 1st quarter. BNP Paribas Arbitrage SA now owns 6,538 shares of the medical instruments supplier’s stock valued at $163,000 after buying an additional 2,872 shares in the last quarter. Oppenheimer Asset Management Inc. raised its stake in LeMaitre Vascular by 3,060.0% during the first quarter. Oppenheimer Asset Management Inc. now owns 7,268 shares of the medical instruments supplier’s stock worth $182,000 after acquiring an additional 7,038 shares in the last quarter. Finally, SG Americas Securities LLC lifted its holdings in shares of LeMaitre Vascular by 129.6% during the first quarter. SG Americas Securities LLC now owns 7,364 shares of the medical instruments supplier’s stock valued at $184,000 after acquiring an additional 4,157 shares during the period. 83.61% of the stock is owned by institutional investors.
Shares of LMAT stock traded up $0.65 during trading on Friday, hitting $32.79. 9,927 shares of the company were exchanged, compared to its average volume of 135,605. The firm has a market capitalization of $650.10 million, a price-to-earnings ratio of 39.68, a P/E/G ratio of 4.02 and a beta of 1.37. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.03 and a current ratio of 2.07. The business’s 50-day simple moving average is $30.34 and its 200 day simple moving average is $27.20. LeMaitre Vascular has a twelve month low of $18.76 and a twelve month high of $38.64.
LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Thursday, July 23rd. The medical instruments supplier reported $0.17 EPS for the quarter, beating the consensus estimate of $0.01 by $0.16. The business had revenue of $24.85 million for the quarter, compared to analysts’ expectations of $15.58 million. LeMaitre Vascular had a net margin of 14.36% and a return on equity of 11.13%. On average, equities analysts forecast that LeMaitre Vascular will post 0.77 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Thursday, September 10th. Investors of record on Thursday, August 27th were given a dividend of $0.095 per share. This represents a $0.38 dividend on an annualized basis and a yield of 1.16%. The ex-dividend date was Wednesday, August 26th. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 43.18%.
LeMaitre Vascular Company Profile
LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.
Featured Story: Balance Sheet
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.